DiaMedica Therapeutics Inc. Common Stock/DMAC

$2.37

-0.83%
-
1D1W1MYTD1YMAX

About DiaMedica Therapeutics Inc. Common Stock

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.

Ticker

DMAC

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Rick Pauls

Employees

18

Headquarters

Minneapolis, United States

DMAC Metrics

BasicAdvanced
$90.72M
Market cap
-
P/E ratio
-$0.62
EPS
1.76
Beta
-
Dividend rate
$90.72M
1.76314
$4.75
$1.50
44.55K
19.266
0.002
0.008
-43.77%
-46.77%
-46.37%
1.777
1.777
-19.27%

What the Analysts think about DMAC

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 3 analysts.
195.36% upside
High $8.00
Low $6.00
$2.37
Current price
$7.00
Average price target

DMAC Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-5.1M
15.91%
Profit margin
0%
-

DMAC Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 0%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.20
-$0.16
-$0.12
-$0.14
-
Expected
-$0.16
-$0.18
-$0.13
-$0.14
-$0.16
Surprise
25%
-9.43%
-5.26%
0%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for DiaMedica Therapeutics Inc. Common Stock stock?

DiaMedica Therapeutics Inc. Common Stock (DMAC) has a market cap of $90.72M as of April 17, 2024.

What is the P/E ratio for DiaMedica Therapeutics Inc. Common Stock stock?

The price to earnings (P/E) ratio for DiaMedica Therapeutics Inc. Common Stock (DMAC) stock is 0 as of April 17, 2024.

Does DiaMedica Therapeutics Inc. Common Stock stock pay dividends?

No, DiaMedica Therapeutics Inc. Common Stock (DMAC) stock does not pay dividends to its shareholders as of April 17, 2024.

When is the next DiaMedica Therapeutics Inc. Common Stock dividend payment date?

DiaMedica Therapeutics Inc. Common Stock (DMAC) stock does not pay dividends to its shareholders.

What is the beta indicator for DiaMedica Therapeutics Inc. Common Stock?

DiaMedica Therapeutics Inc. Common Stock (DMAC) has a beta rating of 1.76. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the DiaMedica Therapeutics Inc. Common Stock stock price target?

The target price for DiaMedica Therapeutics Inc. Common Stock (DMAC) stock is $7, which is 195.36% above the current price of $2.37. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell DiaMedica Therapeutics Inc. Common Stock stock

Buy or sell DiaMedica Therapeutics Inc. Common Stock stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing